Sartorius Stedim Biotech SA 2020 IR
The report highlights Sartorius Stedim Biotech's strong financial and operational performance in 2020, driven by robust organic growth, strategic acquisitions, and significant pandemic-related demand for coronavirus vaccine and Covid-19 therapeutic production. Sales revenue surged by 32.6% to €1,910.1 million, and underlying EBITDA rose by 43.5% to €604.7 million. The company expanded its global production capacities and completed key acquisitions, including selected life science businesses from Danaher Corporation, BIA Separations, and WaterSep BioSeparations. Additionally, the company significantly increased its workforce to over 7,500 employees to meet the unprecedented demand.
Company: Sartorius Stedim Biotech SA
Sector: Manufacturing
Country: France
Year: 2020
Type: IR
Pages: 252
Back to company
Sartorius Stedim Biotech SA
Universal Registration Document Including The Annual Financial Report
The report highlights Sartorius Stedim Biotech's strong financial and operational performance in 2020, driven by robust organic growth, strategic acquisitions, and significant pandemic-related demand for coronavirus vaccine and Covid-19 therapeutic production. Sales revenue surged by 32.6% to €1,910.1 million, and underlying EBITDA rose by 43.5% to €604.7 million. The company expanded its global production capacities and completed key acquisitions, including selected life science businesses from Danaher Corporation, BIA Separations, and WaterSep BioSeparations. Additionally, the company significantly increased its workforce to over 7,500 employees to meet the unprecedented demand.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees